Carnosine Supplementation Mitigates Brain Tissue Markers of Oxidative Stress in a Rat Model of Fulminant Hepatic Failure

Akram Jamshidzadeh¹,², Narges Abdoli³, Hossein Niknahad¹,², Negar Azarpira⁴, Somayeh Mousavi², Elnaz Mardani², Mojgan Abasvali², Reza Heidari¹,2

¹Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
²Department of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
³Iran Food and Drug Administration (IFDA), Ministry of Health, Tehran, Iran.
⁴Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Abstract

Fulminant hepatic failure is a deleterious clinical complication, which leads to hyperammonemia. Ammonia is a noxious neurotoxic agent, which affects brain tissue through different mechanisms. On the other hand, it is well-known that oxidative stress and its consequences play a major role in the pathogenesis of ammonia-induced brain injury. Carnosine is a dipeptide abundantly found in the human central nervous system (CNS). This peptide is widely investigated for its neuroprotective properties. The current study aimed to evaluate the effect of carnosine supplementation on oxidative stress markers in the brain tissue of a rat model of fulminant hepatic failure and hyperammonemia. Animals received thioacetamide (400 mg/kg, i.p, for three consecutive days at 24-hr intervals) as a model of acute liver failure and hyperammonemia. Several serum biochemical parameters, in addition to plasma and brain ammonia level, were monitored. On the other hand, brain tissue markers of oxidative stress including reactive oxygen species (ROS) formation, lipid peroxidation, tissue glutathione content, and total antioxidant capacity were measured. It was found that plasma and brain ammonia was increased, and serum markers of liver injury were significantly elevated in the thioacetamide-treated group. On the other hand, an increase in markers of oxidative stress, including ROS formation, lipid peroxidation, glutathione depletion, and decreased tissue antioxidant capacity, was evident in the brain of thioacetamide-treated animals. It was found that carnosine supplementation (250, 500, and 1000 mg/kg, i.p) decreased serum markers of liver injury, mitigated brain, and plasma ammonia level, and alleviated brain tissue markers of oxidative stress. These data suggest carnosine as a potential neuroprotective agent with therapeutic capability against ammonia-induced CNS injury during hepatic encephalopathy.

Keywords: Hepatic encephalopathy, Hyperammonemia, Neurotoxin, Oxidative stress, Peptide, Protective

1. Introduction

Acute or chronic liver failure with different etiologies might lead to hepatic encephalopathy (HE) and hyperammonemia (1). Although the exact cause of HE-induced organ injury is not known, there is agreement on the critical role of ammonia in this complication (2). Normally, ammonia is metabolized to urea by the liver. When the liver is damaged, this organ is not able to metabolize ammonia. Hence, plasma level of am-
monia is elevated in the systemic circulation; and finally, this toxic chemical reaches the brain. Ammonia is a well-known neurotoxin, which affects the CNS by several mechanisms (3, 4). Ammonia has several direct toxic effects on neurons and astrocytes (4). It has been found that ammonia causes brain edema, oxidative stress, and neuroinflammation when its level is raised during HE (5). Consequently, a suppression of the brain function occurs in patients with HE (5).

Oxidative stress and its associated biological consequences are known to be implicated in ammonia neurotoxicity (3, 6). It has been reported that ammonia caused severe oxidative stress, lipid peroxidation, and defect in cellular antioxidant mechanisms in the CNS (7-12). Hence, antioxidants that easily reaches the brain might have therapeutic value in HE-associated CNS complications.

Carnosine (b-alanyl-L-histidine) is an endogenously-synthesized dipeptide found at high concentrations in different tissues of mammals (13, 14). Numerous biological roles are attributed to carnosine (15, 16). Several pharmacological properties also have been identified for this peptide (17, 18). It has been found that carnosine significantly mitigated xenobiotics-induced injury in different experimental models (19-23). Carnosine supplementation also was shown to have protective effects against several pathological conditions (24-30). Reactive species scavenging ability and antioxidant properties of carnosine are tightly attributed to its protective properties in different biological systems (19, 21, 31, 32).

Carnosine is also known as a neuropeptide (33, 34). Several studies mentioned the importance of carnosine in the CNS (15, 33-35). Carnosine administration has been shown to be effective against a wide range of CNS disorders including Parkinson and Alzheimer disease (36, 37). Furthermore, it has been found that carnosine serves as a protective agent against a number of neurotoxic chemicals (35, 38-40). Interestingly, the neuroprotective effects of this peptide against brain ischemia and stroke are clinically investigated, and there is substantial evidence suggesting carnosine as a protective agent against brain ischemia (41-43). All these findings indicate that this peptide might also act as an effective protective agent against ammonia-induced CNS complications.

The current investigation was designed to evaluate the neuroprotective capability of carnosine in a rat model of acute liver failure and hyperammonemia. Rats received thioacetamide as an animal model of fulminant hepatic failure. Then, plasma and brain ammonia level along with serum biomarkers of liver injury were monitored. Moreover, brain markers of oxidative stress were measured to investigate the effect of carnosine supplementation on HE-associated CNS injury.

2. Material and methods

2.1. Chemicals

Carnosine, 4,2 hydroxyethyl,1-piperazine ethane sulfonic acid (HEPES), 6-hydroxy-2,5,7,8-tetramethyl chroman-2-carboxylic acid (Trolox), thiobarbituric acid (TBA), fatty acid-free bovine serum albumin (BSA) fraction V, dithiobis-2-nitrobenzoic acid (DTNB), glutathione (GSH), 2′,7′ dichlorofluorescein diacetate (DCFH-DA), malondialdehyde (MDA), sucrose, KCl, Na2HPO4, MgCl2, dithiothreitol, Coomassie brilliant blue, ethylene glycol-bis (2-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), and ethylenediaminetetraacetic acid (EDTA) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Trichloroacetic acids (TCA), ammonium chloride, and hydroxymethyl amino methane hydrochloride (Tris-HCl) were purchased from Merck (Darmstadt, Germany). All salts for preparing buffer solutions were of analytical grade and obtained from Merck (Darmstadt, Germany).

2.2. Animals

Male Sprague-Dawley rats (n=48; 200-250 g weight) were obtained from the Animal Breeding Center, Shiraz University of Medical Sciences, Shiraz, Iran. Animals were housed in plastic cages over hardwood bedding. There was an environmental temperature of 23±1 °C and a 12L: 12D photoschedule along with a 40% of relative humidity. Rats were allowed free access to a normal standard chow diet and tap water. All the experiments were performed in conformity with the guidance for care and use of experimental animals approved by a local ethics committee.
in Shiraz University of Medical Sciences, Shiraz, Iran (#95-01-36-12054).

2.3. Animal model of fulminant hepatic failure

Thioacetamide is extensively used as a model of acute hepatic failure (44). In the current study, thioacetamide-induced fulminant hepatic failure was achieved by three consecutive intraperitoneal (i.p) injections of thioacetamide (400 mg/kg) to rats (n=48; 6 rats/group) at 24-hr intervals (45). Carnosine was administered for three consecutive days, two hr after each dose of thioacetamide. The treatments were as follow: 1) control (vehicle-treated); 2) thioacetamide; 3) thioacetamide+carnosine 250 mg/kg; 4) thioacetamide+carnosine 500 mg/kg; 5) thioacetamide+carnosine 1000 mg/kg; 6) carnosine 1000 mg/kg.

Animals were anesthetized (thiopental, 80 mg/kg, i.p) 24 hr after the last dose of thioacetamide, and their blood, brain, and liver samples were collected. As mentioned in previous studies, supportive therapy by administering 5% dextrose (2.5 ml/kg body weight, S.C) containing 0.45% sodium chloride and 0.2% potassium chloride, was given to avoid weight loss, hypoglycemia, and renal failure in thioacetamide-induced hepatic failure model (45). Control animals (vehicle-treated) received normal saline as the thioacetamide solvent. The sole carnosine (1000 mg/kg, i.p) was administered to ensure its safety.

2.4. Blood biochemistry and tissue histopathology

Standard commercial kits and a MindrayBS-200® auto analyzer were used to measure serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase (LDH) (46). Plasma ammonia was measured with standard kits based on the absorbance photometry method of phenate-hypochlorate reaction (47). To determine brain ammonia content, samples (100 mg) of the forebrain (cerebral cortex) were dissected, homogenized, and deproteinized in 3 ml of ice-cooled lysis solution (Trichloroacetic acid, 6%, w/v). After centrifugation (12000g, 10 min, 4 °C), the supernatant was collected and neutralized with potassium carbonate (KHCO₃; 2 mol/l, pH=7). Afterward, brain ammonia content was measured using standard kits (47). For histopathological evaluation, samples of liver were fixed in phosphate-buffered formalin solution (0.4% sodium phosphate monobasic, NaH₂PO₄, 0.64% sodium phosphate dibasic, Na₂HPO₄, and 10% formaldehyde in distilled water) (48, 49). Paraffin-embedded sections of liver were prepared and stained with haematoxylin and eosin (H&E) before light microscope viewing.

2.5. Reactive oxygen species formation

Reactive oxygen species (ROS) formation in the brain tissue was estimated as previously described (50, 51). Briefly, samples of brain tissue were homogenized in 5 ml of ice-cooled (4 °C) Tris-HCl buffer (40 mM, pH=7.4). Samples of the resulted tissue homogenate (100 µl) were mixed with Tris-HCl buffer (1 ml; pH=7.4 4 °C) and 2′, 7′ dichlorofluorescein diacetate (Final concentration 10 µM) (52, 53). The mixture was incubated at 37 °C (15 min, in dark). Finally, the fluorescence intensity (FI) of the samples was assessed using a FLUOstar Omega® multi functional microplate reader at λ excitation=485 nm and λ emission=525 nm (50, 54).

2.6. Brain tissue glutathione content

Tissue samples were homogenized in 4 ml of ice-cooled EDTA (20 mM; 4 °C). Then, 2.5 ml of the prepared homogenate were added to 2 ml of distilled water (4 °C) and 1 ml of trichloroacetic acid (50% w/v; 4 °C). Samples were mixed well and centrifuged (10,000 g, 4 °C, 25 min). Afterward, 1 ml of the supernatant was mixed with 4ml of Tris buffer (pH=8.9; 4 °C), and 100 µl of DTNB (10 mM in methanol) (52,53). The absorbance of the developed color was measured at λ=412 nm using an Ultrospec 2000®UV spectrophotometer (Pharmacia Biotech, Uppsala, Sweden) (55).

2.7. Lipid peroxidation

The thiobarbituric acid reactive substances (TBARS) test was used as a method to assess lipid peroxidation in the brain tissue (55). The reaction mixture was consisted of 500 µl of tissue homogenate (10% w/v in KCl, 1.15%), 1 ml of thiobarbituric acid (0.375%, w/v), and 3 ml of metaphosphoric acid (1% w/v, pH=2). Samples
were mixed well and heated (100 °C; 45 min). Then, the mixture was cooled, and 2 ml of n-butan-ol was added. Samples were vigorously vortexed and centrifuged (10,000 g for 5 min). Finally, the absorbance of developed color in n-butanol phase was read at λ=532 nm using an Ultrospec 2000® UV spectrophotometer (Pharmacia Biotech, Uppsala, Sweden) (55).

2.8. Ferric reducing antioxidant power (FRAP) of the brain tissue

FRAP assay is a method to measure the formation of a blue colored Fe$^{2+}$-tripyridyl-tria-zine compound from the colorless oxidized Fe$^{3+}$, which is formed by the action of electron-donating antioxidants (56, 57). In the current study, the working FRAP reagent was prepared by mixing 10 volumes of acetate buffer (300 mmol/L, pH=3.6), with 1 volume of TPTZ (10 mmol/L in 40 mmol/L hydrochloric acid) and 1 volume of ferric chloride (20 mmol/L). All solutions were freshly prepared.

Tissue was homogenized in an ice-cooled Tris-HCl buffer (250 mM Tris-HCl, 200 mM sucrose, and 5 mM DTT, pH=7.4 °C) (57). Then, 50 µl of tissue homogenate and 150 µl of deionized water was added to 1.5 ml of the FRAP reagent (58). The reaction mixture was incubated at 37°C for 5 min in dark. Finally, the absorbance of developed color was measured at λ=595 nm by an Ultrospec 2000® UV spectrophotometer (Pharmacia Biotech, Uppsala, Sweden) (51, 59).

2.9. Statistical analysis

Data are given as Mean ± SD. Comparison of data sets was performed by the one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons as the post hoc test. Values of $P$<0.05 were considered statistically significant.

3. Results

Thioacetamide treatment (400 mg/kg, i.p, 24 hr intervals for three consecutive days) caused

Figure 1. Serum biochemical measurements. TAA: Thioacetamide; Carn.: Camosine. Data are given as Mean±SD (n=8).

***Indicates significantly different as compared with the control group ($P$<0.001).

aIndicates significantly different as compared with TAA group ($P$<0.001).
acute hepatic failure as judged by drastic elevation in serum markers of liver injury (Figure 1). On the other hand, liver tissue histopathological changes in the thioacetamide-treated group consisted of severe necrosis, ballooning degeneration, fatty changes, and inflammation (Figure 2). It was found that carnosine (250, 500, and 1000 mg/kg, i.p) decreased serum biomarkers of liver
injury (Figure 1). This peptide (250, 500, and 1000 mg/kg, i.p) also alleviated liver histopathological changes in thioacetamide-treated animals (Figure 2), and no sign of tissue necrosis was found in 1000 mg/k carnosine-treated animals (Figure 2).

A high-level of ammonia was detected in the plasma of thioacetamide-treated animals (Figure 3). Brain tissue ammonia level was also higher in thioacetamide-treated rats in comparison with the control group (Figure 3). It was found that carnosine supplementation (250, 500, and 1000 mg/kg, i.p) significantly decreased both plasma and brain ammonia level (Figure 3).

Brain tissue markers of oxidative stress were significantly higher in thioacetamide-treated group (Figure 4). A high level of ROS along with severe lipid peroxidation and glutathione depletion was detected in thioacetamide-treated rats (Figure 4). Moreover, brain tissue antioxidant capacity was significantly decreased in thioacetamide-treated animals (Figure 4). It was found that carnosine treatment (250, 500, and 1000 mg/kg, i.p) signifi-

---

**Figure 4.** Effect of carnosine supplementation on brain tissue markers of oxidative stress in hyperammonemic animals. TAA: Thioacetamide; Carn.: Carnosine.

Data are given as Mean±SD (n=8).

***Indicates significantly different as compared with the control group (P<0.001).

aIndicates significantly different as compared with TAA group (P<0.001).
cantly mitigated brain tissue markers of oxidative stress in hyperammonemic animals (Figure 4). Moreover, lower level of ROS and lipid peroxidation was detected in carnosine-supplemented rats (Figure 4). Carnosine treatment also preserved brain antioxidant capacity and prevented tissue glutathione depletion (Figure 4).

4. Discussion

Oxidative stress and its associated complications are known to be involved in the pathogenesis of hyperammonemia-induced brain injury (7-9, 60-62). Therefore, antioxidant molecules might play a role in attenuating ammonia neurotoxicity. Carnosine is an endogenously-found peptide, with a high concentration in the human brain. Several pharmacological properties including antioxidant and radical scavenging activities are attributed to this peptide. In the current study, it was found that carnosine supplementation (250, 500, and 1000 mg/kg, i.p) to rats with acute liver failure and hyperammonemia, attenuated brain tissue markers of oxidative stress. Furthermore, carnosine treatment decreased brain and plasma level of ammonia.

It is well-known that ammonia-induced oxidative stress in the brain tissue and its deleterious consequences play a major role in the neurotoxicity induced by this chemical (9, 63). In accordance with previous studies, we found that acute liver failure and its associated hyperammonemia caused significant lipid peroxidation and a decrease in glutathione content of the brain tissue (Figures 4). On the other hand, carnosine is a well-known antioxidant and scavenger of reactive intermediates (35, 64-66). This peptide was also reported to boost antioxidant defense mechanisms and preserves cellular glutathione reservoirs (43, 67). In our experiments, carnosine (250, 500, and 1000 mg/kg, i.p) effectively alleviated oxidative stress and its consequences in hyperammonemic animals. Hence, the antioxidant capacity of carnosine might play a major role in its protective properties against ammonia-induced neurotoxicity.

Mitochondrial dysfunction and brain energy crisis is a major mechanism involved in ammonia-induced neurotoxicity. It was found that ammonia caused a significant increase in brain mitochondrial ROS (68-70). Previous studies indicated that carnosine effectively preserves mitochondrial membrane potential (71, 72). Mitochondrial pH gradient and membrane potential are important factors for mitochondrial function (71). Hence, chemicals that are able to localize in the mitochondrial matrix and regulate matrix pH are capable of preserving mitochondrial membrane

Figure 5. Schematic representation of the protective role of carnosine against ammonia toxicity during fulminant liver failure and hepatic encephalopathy.
potential. Furthermore, the collapse of mitochondrial membrane potential, along with impaired mitochondrial defense mechanisms were documented in ammonia-exposed mitochondria (68-70). Previously, we found that carnosine significantly mitigated ammonia-induced mitochondrial dysfunction in vitro (69). Hence, mitochondrial protecting properties of carnosine might be involved, at least in part, in the neuroprotective properties of this peptide in brain tissue of hyperammonemic models.

Interestingly, it was reported that carnosine significantly improved behavioral disturbances in an in vivo model of acute liver failure (73). Previously, we found that carnosine supplementation effectively improved locomotor activity in cirrhotic rats (74). Milewski et al. proposed that the beneficial effects of carnosine in the brain tissue of acute liver failure animal model might be mediated through its antioxidant capacity (73). In the investigation by Milewski et al., only one dose of carnosine was administered (100 mg/kg, i.p., 2 hr before thioacetamide challenge). On the other hand, they didn’t observe significant changes in some antioxidant parameters in carnosine-treated animals (73). In the current study, which is actually a part of a greater investigation on the role of carnosine supplementation on the brain bioenergetics failure during HE, we found that higher doses of carnosine (250, 500, and 1000 mg/kg) effectively alleviated brain markers of oxidative stress in HE. Moreover, we detected lower plasma and brain ammonia level in carnosine supplemented animals (Figure 3). On the other hand, this peptide effectively preserved brain mitochondrial function during HE episodes (Data not shown). Furthermore, in an in vitro investigation on the role of carnosine supplementation on ammonia-induced mitochondrial dysfunction, we found that carnosine could significantly preserve mitochondrial function in a hyperammonemic environment (69). Tremor, rigidity, akinesia, athetosis, impaired locomotor activity, and cognitive dysfunction are major HE-associated neuropsychiatric symptoms (1) (Figure 5). It was shown that carnosine supplementation effectively mitigated ammonia-induced neuropsychiatric symptoms both in acute and chronic HE models (70, 73). All these data indicate that carnosine could be an eligible therapeutic option against ammonia neurotoxicity (Figure 5).

The beneficial effects of carnosine in HE could be due to its direct effects on brain tissue, where this peptide encounters oxidative stress and its associated complications. On the other hand, carnosine could affect the liver and prevent an increase in plasma and brain ammonia (70) (Figure 5). Hence, the hepatoprotective effects of carnosine might also play a role in the neuroprotection provided by this peptide (Figure 5).

In conclusion, our data suggest that carnosine exhibits a robust protective effect against ammonia-induced oxidative damage in the CNS. Hence, carnosine might be an ideal therapeutic option against HE. However, further research in different animal models of hepatic failure and hyperammonemia is needed for understanding the precise mechanism of action of carnosine against ammonia-induced CNS injury.

**Acknowledgment**

The authors thank Pharmaceutical Sciences Research Center (PSRC) and the Vice-Chancellor of Research Affairs of Shiraz University of Medical Sciences for providing technical and financial support of the current investigation (Grant number 12054/9741/9823).

**Conflict of Interest**

None declared.

---

5. References


Carnosine neuroprotection in rats


54. Socci DJ, Bjugstad KB, Jones HC, Pattisapu JV, Arendash GW. Evidence that oxidative stress is associated with the pathophysiology of inherited hydrocephalus in the H-Tx rat model. *Exp Neurol.* 1999;155;109-17.


56. Katalinic V, Modun D, Music I, Boban M. Gender differences in antioxidant capacity of rat tissues determined by 2,2'-azinobis (3-ethylbenzothiazoline 6-sulfonate; ABTS) and ferric reducing antioxidant power (FRAP) assays. *Comp Biochem Physiol Toxicol Pharmacol.* 2005;140;47-52.


72. Shen Y, Pe P, Fan Y-y, Zhang J-x, Yan H-j, Hu W-w, Ohtsu H, Chen Z. Carnosine protects against permanent cerebral ischemia in his-
Akram Jamshidzadeh et al.

